DEERFIELD, Ill.--(BUSINESS WIRE)--
Baxter International Inc. (NYSE:BAX) today announced an approximately
19% increase in the company’s quarterly dividend rate. This rate
increase was made in connection with the declaration of a quarterly cash
dividend of $0.19 per share of common stock (up from $0.16 per share),
payable on July 2, 2018, to stockholders of record as of June 1, 2018.
The indicated annual dividend rate is now $0.76 per share of common
stock.
“Baxter is pleased to raise our quarterly dividend rate,” said José
(Joe) E. Almeida, chairman and chief executive officer. “The new rate
reflects our strong financial position and continued transformation to
deliver industry-leading performance, as we strategically deploy capital
to fuel growth and enhance stockholder value.”
About Baxter
Baxter provides a broad portfolio of essential healthcare products
across its portfolio, including acute and chronic dialysis therapies;
sterile IV solutions; infusion systems and devices; parenteral nutrition
therapies; inhaled anesthetics; generic injectable pharmaceuticals; and
surgical hemostat and sealant products. The company’s global footprint
and the critical nature of its products and services play a key role in
expanding access to healthcare in emerging and developed countries.
Baxter’s employees worldwide are building upon the company’s rich
heritage of medical breakthroughs to advance the next generation of
healthcare innovations that enable patient care.
This release includes forward-looking statements concerning Baxter's
dividends and rates thereof. The statements are based on assumptions
about many important factors, including the following, which could cause
actual results to differ materially from those in the forward-looking
statements: continued strength in the company’s financial position,
including cash flows; alternative uses of funds including, but not
limited to dividends, share repurchases, research and development,
business development transactions and other investments in the company’s
businesses; and other risks identified in the company's most recent
filing on Form 10-K and other SEC filings, all of which are available on
Baxter’s website. Baxter does not undertake to update its
forward-looking statements.
View source version on businesswire.com:
https://www.businesswire.com/news/home/20180508005959/en/
Baxter International Inc.
Media Contact
Bill Rader,
(224) 948-5353
media@baxter.com
or
Investor
Contact
Clare Trachtman, (224) 948-3085
Source: Baxter International Inc.